Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 2, Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus Participating in Extension Protocols 217-102, 103, or 104

NCT00143247 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00143247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00143247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 2, Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus Participating in Extension Protocols 217-102, 103, or 104
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2003
Completion date
January 31, 2008
Enrollment
173 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus